Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Patrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Thoracic Cancer
|
September 14, 2022
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
Logan C Tyler, Anh T Le, Nan Chen, et al.
Molecular Oncology
|
March 26, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Molecular Oncology
|
March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Jessica W Chen, William Jacot, Javier Cortés, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial
Chiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2026
TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors
David M Thomas, Jeong Eun Kim, Fabrice Barlesi, et al.
Plos One
|
February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers
Erica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Nature
|
July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Patrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Thoracic Cancer
|
September 14, 2022
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
Logan C Tyler, Anh T Le, Nan Chen, et al.
Molecular Oncology
|
March 26, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Molecular Oncology
|
March 9, 2023
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Jessica W Chen, William Jacot, Javier Cortés, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial
Chiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2026
TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors
David M Thomas, Jeong Eun Kim, Fabrice Barlesi, et al.
Plos One
|
February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers
Erica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Nature
|
July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Page
of 7